Fresh off an $11.5B car­dio wa­ger, Mer­ck promis­es in­vestors a megablock­buster fu­ture in a re­turn to the glo­ry days

Mer­ck’s de­ci­sion to out­bid Bris­tol My­ers Squibb dur­ing the $11.5 bil­lion auc­tion of Ac­celeron raised the bar con­sid­er­ably for the phar­ma gi­ant’s car­dio­vas­cu­lar drug port­fo­lio. And to­day a Mer­ck team came back with a big promise on the pay­off to come, tout­ing the multi­bil­lion-dol­lar sales po­ten­tial of the lead drug in the deal that opens up the path to $10 bil­lion in new peak sales po­ten­tial for the car­dio pipeline by the mid-2030s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER